EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Added Value of [ 18F ] PSMA ‐1007 PET / CT and PET / MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management

Bendik S Abrahamsen iD, Torgrim Tandstad, Bjørg Y Aksnessæther, Trond V Bogsrud, Miguel Castillejo, Eivor Hernes, Håkon Johansen, Thomas M I Keil, Ingerid S Knudtsen, Sverre Langørgen, Kirsten M Selnæs, Tone F Bathen iD und 1 weitere

Journal of Magnetic Resonance Imaging · 2025

DOI: 10.1002/jmri.29386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, 2025. Verfasst von Bendik S Abrahamsen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Magnetic Resonance Imaging, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 180°N-Norwegian Nuclear Medicine Consortium, Norwegian Cancer Society and Prostatakreftforeningen, Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) can change management in a large fraction of patients with biochemically recurrent prostate cancer (BCR).

Purpose

To investigate the added value of PET to MRI and CT for this patient group, and to explore whether the choice of the PET paired modality (PET/MRI vs. PET/CT) impacts detection rates and clinical management. Study Type Retrospective. Subjects 41 patients with BCR (median age [range]: 68 [55–78]). Field Strength/Sequence 3T, including T1‐weighted gradient echo (GRE), T2‐weighted turbo spin echo (TSE) and dynamic contrast‐enhanced GRE sequences, diffusion‐weighted echo‐planar imaging, and a T1‐weighted TSE spine sequence. In addition to MRI, [ 18 F]PSMA‐1007 PET and low‐dose CT were acquired on the same day. Assessment Images were reported using a five‐point Likert scale by two teams each consisting of a radiologist and a nuclear medicine physician. The radiologist performed a reading using CT and MRI data and a joint reading between radiologist and nuclear medicine physician was performed using MRI, CT, and PET from either PET/MRI or PET/CT. Findings were presented to an oncologist to create intended treatment plans. Intrareader and interreader agreement analysis was performed. Statistical Tests McNemar test, Cohen's κ , and intraclass correlation coefficients. A P ‐value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyMagnetic Resonance ImagingNeoplasm Recurrence, LocalHumansMaleAgedRetrospective StudiesMiddle AgedPositron-Emission TomographyNiacinamideOligopeptidesMultimodal ImagingRadiopharmaceuticalsProstateProstate-Specific Antigen

Stichwörter der Autor:innen

PET/CTPET/MRIPSMA PETbiochemical recurrenceprostate cancer

Substanzen

PSMA-1007NiacinamideOligopeptidesRadiopharmaceuticalsProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.
  • The Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Oncology, Ålesund Hospital, Møre and Romsdal Hospital Trust, Ålesund, Norway.
  • PET Imaging Centre, University Hospital of North Norway, Tromsø, Norway.
  • PET-Centre, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Bendik S Abrahamsen, Tone F Bathen, Mattijs Elschot

Förderung

  • 180°N-Norwegian Nuclear Medicine Consortium
  • Norwegian Cancer Society and Prostatakreftforeningen
  • Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology

Zitieren

APA

Abrahamsen, B. S., Tandstad, T., Aksnessæther, B. Y., Bogsrud, T. V., Castillejo, M., Hernes, E., Johansen, H., Keil, T. M. I., Knudtsen, I. S., Langørgen, S., Selnæs, K. M., Bathen, T. F., & Elschot, M. (2025). Added Value of [ 18F ] PSMA ‐1007 PET / CT and PET / MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.29386

Vancouver

Abrahamsen BS, Tandstad T, Aksnessæther BY, Bogsrud TV, Castillejo M, Hernes E, et al. Added Value of [ 18F ] PSMA ‐1007 PET / CT and PET / MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management. Journal of Magnetic Resonance Imaging. 2025. doi:10.1002/jmri.29386

BibTeX
@article{Abrahamsen2025,
  author = {Abrahamsen, Bendik S and Tandstad, Torgrim and Aksnessæther, Bjørg Y and Bogsrud, Trond V and Castillejo, Miguel and Hernes, Eivor and Johansen, Håkon and Keil, Thomas M I and Knudtsen, Ingerid S and Langørgen, Sverre and Selnæs, Kirsten M and Bathen, Tone F and Elschot, Mattijs},
  title = {Added Value of [ 18F ] PSMA ‐1007 PET / CT and PET / MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management},
  journal = {Journal of Magnetic Resonance Imaging},
  year = {2025},
  doi = {10.1002/jmri.29386}
}
Kostenlos starten →